MENLO PARK, Calif., Feb. 27, 2025 /PRNewswire/ — MyOme, Inc., a leading clinical whole genome testing and polygenic risk modelling (PRS) company, is proud to announce the launch of its coronary artery ...
Introduction: The positive outcomes of the COMPASS trial raise questions about the proportion of patients who could benefit from additional therapy with rivaroxaban in real-world practice. Objectives: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results